The utility of PET/CT with 18F-FDG in the study of Hodgkin's lymphoma and non-Hodgkin's lymphoma

Authors

  • Marta Milhões Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa. Lisboa, Portugal.
  • José Rafael Infante Serviço de Medicina Nuclear, Hospital Infanta Cristina. Badajoz, Espanha.
  • Juan Rayo Madrid Serviço de Medicina Nuclear, Hospital Infanta Cristina. Badajoz, Espanha.
  • L. B. Garcia Serviço de Medicina Nuclear, Hospital Infanta Cristina. Badajoz, Espanha.
  • Lina Vieira Área Científica de Medicina Nuclear, Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa. Lisboa, Portugal.

DOI:

https://doi.org/10.25758/set.264

Keywords:

PET/CT, 18F-FDG, Hodgkin's lymphoma, Non-Hodgkin's lymphoma

Abstract

Lymphomas are tumors established in the lymphatic system. Due to their heterogeneity, they can be classified as Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL), presenting each type of lymphoma, different prognosis, and chemotherapeutic response. Currently, Photon Emission Tomography/Computed Tomography (PET/CT) is considered the "image" of excellence in the study of this pathology. In this context, it is of interest in this article to verify the usefulness of the PET/CT technique and to correlate the value of Standard Uptake Value (SUV) obtained by PET with the histological stage of lymphoma and the response to chemotherapeutic treatment. Methodology - We studied retrospectively 356 studies for 231 patients that did a PET/CT for staging, or evaluation of a mass or of the response to treatment. After administration of an average activity of 18F-FDG of 288.6 MBq, images were acquired on a PET/CT GE Discovery ST. These results were compared with the clinical data of patients. Results - Significant differences were found between age vs type of lymphoma. No significant differences were found between: the value of SUVmaxim nodes, extra-nodal lesions, and their value of SUV for the type of lymphoma. It verified the influence of PET/CT in the alteration of the stage of lymphoma as well as the therapeutic decision. Finally were found respectively the following values of sensitivity, specificity, and accuracy: were 98%, 79%, and 88%. Conclusions - The results show the importance of imaging PET/CT in evaluating the stage of the tumor and its role in monitoring and change of therapeutic decisions.

References

Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med. 2006. 47(8):1326-34.

Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assessment of Hodgkin’s disease and aggressive Non-Hodgkin’s lymphoma: a systematic review. J Nucl Med. 2008;49(1):13-21.

Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nuc Med. 2002;43(8):1018-27.

Juweid ME. 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin’s disease and aggressive Non-Hodgkin’s lymphoma: where is the evidence? J Nuc Med. 2008;49(1):9-12.

Tatsumi M, Kitayama H, Sugahara H, Tokita N, Nakamura H, Kanakura Y, et al. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin’s lymphoma. J Nucl Med. 2001;42(4):601-8.

Guay C, Lépine M, Verreault J, Bénard F. Prognostic value of PET using 18F-FDG in Hodgkin’s disease for posttreatment evaluation. J Nucl Med. 2003;44(8):1225-31.

Palestro CJ, Rini JN, Thomas MB. Lymphoma. In: Charron M, editor. Practical pediatric PET imaging. New York: Springer Science; 2006. p. 220-42.

de la Serra Torroba J. Linfoma de Hodgkin. JANO – Medicina y Humanidades. 2003;LXIV(1470):60-4.

Menzel C. Hodgkin’s disease and Non-Hodgkin’s lymphomas. In: Ruhlmann J, Oehr P, Biersack H-J, editors. PET in oncology: basics and clinical application. Berlin: Springer-Verlag; 1999. p. 158-65.

Lynch TB. Lymphom. In: Lynch TB, editor. PET/CT in clinical practice. London: Springer-Verlag; 2007. p. 48-71.

Jerusalem GH, Hustinx R, Rigo P. PET and PET/CT imaging in lymphoma. In: Valk PE, Delbeke D, Bailey DL, Townsend DW, Maisey MN, editors. Positron emission tomography: clinical practice. London: Springer-Verlag; 2006. p. 125-46.

Wong CY, Thie J, Parting-Lynch KJ, Zakalik D, Margolis JH, Gaskill M, et al. Glucose-normalized standardized uptake value from 18F-FDG PET in classifying lymphomas. J Nucl Med. 2005;46(10):1659-63.

Rigacci, L, Vitolo U, Nassi L, Merli F, Gallamini A, Pregno P, et al. Positron emission tomography in the staging of patients with Hodgkin’s lymphoma: a prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol. 2007;86(12):897-903.

Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology. 2005;237(3):1038-45.

Dhanapathi H, Kumar R. F-18 FDG PET/PET-CT in the management of lymphoma. Indian J Med Pediatr Oncol. 2007;28(3):17-23.

Schöder H, Meta J, Yap C, Ariannejad M, Rao J, Pelps ME, et al. Effect of whole-body 18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med. 2001;42(8):1139-43.

Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L, et al. Whole-body FD-PET imaging for staging of Hodgkin’s disease and lymphoma. J Nucl Med. 1997;38(3):343-8.

Metser U, Goor O, Lerman H, Naparstek E, Even-Sapir E. PET–CT of extranodal lymphoma. AJR Am J Roentgenol. 2004;182(6):1579-86.

Chalapud J, Sobrevilla-Calvo P, Rivas-Vera S, Altamirano-Levy J. Marked improvement in detecting the number of involved nodal areas in lymphoma, using 18F-FDG – PET and CT scan. Blood (ASH Meeting Abstracts). 2005;106:abstract 1344.

Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47(5):885-95.

Beyer T, Antoch G, Müller S, Egelhof T, Freudenberg LS, Debatin J, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med. 2004;45 Suppl 1:25S-35S.

Downloads

Published

2009-11-15

Issue

No. 04 (2009): Novembro 2009

Section

Artigos

License

Copyright (c) 2022 Saúde e Tecnologia

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The journal Saúde & Tecnologia offers immediate free access to its content, following the principle that making scientific knowledge available to the public free of charge provides greater worldwide democratization of knowledge.

The journal Saúde & Tecnologia does not charge authors any submission or article processing charges (APC).

All content is licensed under a Creative Commons CC-BY-NC-ND license. Authors have the right to: reproduce their work in physical or digital form for personal, professional, or teaching use, but not for commercial use (including the sale of the right to access the article); deposit on their website, that of their institution or in a repository an exact copy in electronic format of the article published by Saúde & Tecnologia, provided that reference is made to its publication in Saúde & Tecnologia and its content (including symbols identifying the journal) is not altered; publish in a book of which they are authors or editors the total or partial content of the manuscript, provided that reference is made to its publication in Saúde & Tecnologia.

How to Cite

The utility of PET/CT with 18F-FDG in the study of Hodgkin’s lymphoma and non-Hodgkin’s lymphoma. (2009). Saúde & Tecnologia, 04, 28-32. https://doi.org/10.25758/set.264